Trial reportOncology2010
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.
Trial report in Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Rectal Endoscopic Ultrasound in Clinical Practice.Current gastroenterology reports · 2019Review
- Radiotherapy in Combination With Cytokine Treatment.Frontiers in oncology · 2019Review
- Radiotherapy as a New Player in Immuno-Oncology.Cancers · 2018Review
- Radiation therapy and immunotherapy: what is the optimal timing or sequencing?Immunotherapy · 2018Review
- Current clinical trials testing the combination of immunotherapy with radiotherapy.Journal for immunotherapy of cancer · 2016Article
- Endoscopic ultrasound guided interventional procedures.World journal of gastrointestinal endoscopy · 2015Review
- Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.World journal of gastroenterology · 2014Review
- Combinations of immunotherapy and radiation in cancer therapy.Frontiers in oncology · 2014Review
- New horizons for cancer gene therapy.Cancer gene therapy · 2014Article
- Can only chemoradiotherapy and chemotherapy treatment be applied to patients with rectal cancer who could not be operated?Journal of gastrointestinal oncology · 2013Article
- Intratumoral gene therapy injections with a multipronged, multi-side hole needle for rectal carcinoma.Cardiovascular and interventional radiology · 2013Article
- In vivo screening of S100B inhibitors for melanoma therapy.Methods in molecular biology (Clifton, N.J.) · 2013Article
- TNFerade, an innovative cancer immunotherapeutic.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveThe purpose of this pilot study was to evaluate the feasibility and tolerability of weekly intratumoral TNFerade™ injections combined with concurrent capecitabine and radiotherapy in the treatment of patients with locally advanced rectal cancer.
methodsPatients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50.4-54 Gy in combination with capecitabine 937.5 mg/m(2) p.o. b.i.d. TNFerade™ at a dose of 4 × 10(10) particle units was injected into the rectal tumor on the first day of radiotherapy and weekly for a total of 5 injections. Surgery was performed 5-10 weeks after the completion of chemoradiation.
resultsNine patients were enrolled in this pilot trial. The stage was cT2 in 2 patients, cT3 in 6 patients, cT4 in 1 patient, N- in 7 patients and N+ in 2 patients. Eight patients completed all treatments. Grade 3 hematologic toxicity was observed in 2 patients. There was no toxicity directly attributable to the injection procedure. A complete pathologic response was observed in 2 of 9 patients.
conclusionsThis study demonstrates the feasibility of weekly intratumoral TNFerade™ injections during chemoradiotherapy for locally advanced rectal cancer. Pathologic responses with this combination compare favorably to published rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.